Molecular Partners AG
MOLN
$4.04
-$0.09-2.18%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
TipRanks Financial Blog
5/12/2026
-
Globe Newswire
5/4/2026
-
Globe Newswire
5/2/2026
-
The Cerbat Gem
5/1/2026
-
TipRanks Financial Blog
5/1/2026
-
Globe Newswire
5/1/2026
-
MarketBeat
4/22/2026
-
MarketBeat
4/21/2026
-
MarketBeat
4/19/2026
-
TipRanks Financial Blog
4/19/2026
-
The Fly
4/19/2026
-
Globe Newswire
4/14/2026
-
Globe Newswire
4/10/2026
-
Tickeron - Technical Analysis
4/9/2026
-
Tickeron - Technical Analysis
4/7/2026
-
TipRanks Financial Blog
4/3/2026
-
Tickeron - Stocks
4/2/2026
-
Tickeron - Technical Analysis
3/30/2026
-
MarketBeat
3/26/2026
-
Tickeron - Stocks
3/24/2026
-
Tickeron - Technical Analysis
3/23/2026
-
Globe Newswire
3/20/2026
-
Tickeron - Technical Analysis
3/19/2026
-
Globe Newswire
3/18/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 12, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
41 44 755 77 00
Address
Wagistrasse 14
Schlieren, 8952
Schlieren, 8952
Country
Year Founded
Business Description
Sector
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its...
more